Pharmafile Logo

Our key takeaways from ISMPP EU 2026 – Evolving with Purpose: Excellence in an Era of Efficiency

April 13, 2026 |  

Explore Inizio Medical’s key takeaway from ISMPP EU 2026, including AI governance, transparency, patient partnership and evolving impact measurement.

- PMLiVE

Medical publications are navigating a period of rapid change. From artificial intelligence and automation to transparency, governance, patient partnership, and evolving impact measurement, the pressure to deliver faster must now coexist with the responsibility to maintain scientific rigour and trust. 

Inizio Medical’s ISMPP EU 2026 Insights Report captures the most consequential discussions from the meeting and outlines the emerging strategic implications for publication teams. 

More than just a meeting summary, this is Inizio Medical’s informed perspective on how publication practices are evolving and how teams can adapt to ensure they remain efficient, ethical, and impactful in 2026 and beyond. 

Download the full report here. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Exploring MINT: Part 3 – Nigeria

In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.

Exploring MINT: Part 2 – Indonesia

In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...

Pegasus Wins ‘Consultancy of the Year’ at Communiqué Awards 2014

Pegasus, the UK’s leading independent health communications consultancy, picked up the much coveted ‘Consultancy of the Year’ award at last week’s Communiqué Awards 2014, fighting off stiff competition from the...

Free Thinking: Leveraging the ASEAN Market

If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to...

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

The Next Billion Patients

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

Huge Untapped Growth Potential of ASEAN

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

The power of observation in gathering patient insights

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.

Market Insights Can Deliver a Better Patient Experience

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding

Excellence in oncology: Developing an effective biomarker strategy

Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,...